Match tier
Confirmed
Presence
Current · Arkansas
Last published
2025
Sources
OpenAlex · ORCID
Refreshed
2026-08-15
N
Nour Fatema
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Researcher
Also affiliated: Stamford University Bangladesh (2013–2024)
Faculty Researcher
5 h-index
13 pubs
346 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Nour Fatema's research investigates post-translational modifications of enzymes, particularly focusing on lysine acetylation. Her work has examined the functional consequences of lysine acetylation in key metabolic enzymes, including phosphofructokinase isozymes and citric acid cycle enzymes. Fatema has also explored the potential pharmacological applications of natural compounds, such as flavonoids found in Annona species, for their antibiotic effects. Additionally, her research has touched upon immunoinformatic approaches for predicting siRNA to target viral proteins, as demonstrated in her work on monkeypox virus.
Fatema has a publication record of 13 papers, with an h-index of 5 and 319 total citations. She has collaborated with several researchers at the University of Arkansas at Fayetteville, including Chenguang Fan (5 shared publications), Qinglei Gan (3 shared publications), Ruben Michael Ceballos (2 shared publications), and Nazim Uddin Emon (1 shared publication).
Metrics
- h-index: 5
- Publications: 13
- Citations: 346
Selected Publications
-
Functional consequences of lysine acetylation of phosphofructokinase isozymes (2025)
-
Characterizing lysine acetylation of glucokinase (2023)
-
In silico prediction of siRNA to silence the SARS-CoV-2 omicron variant targeting BA.4, BA.5, BQ.1, BQ1.1. and XBB: an alternative to traditional therapeutics (2023)
-
Studying lysine acetylation of citric acid cycle enzymes by genetic code expansion (2023)
-
In-Silico Prediction of Sirna to Silence the Sars-Cov-2 Omicron Variant Specifically Ba.4 and Ba.5: An Alternative to Traditional Therapeutics (2023)
-
Modifications of cellulose-based biomaterials for biomedical applications (2022)
-
Comparisons of Catalytic Efficiency during the Reduction of Lignocellulosic Substrates between Free Enzyme and Enzyme bound to Mobile Enzyme Sequestration Platforms (MESP) (2021)
-
Comparisons of catalytic efficiency during the reduction of lignocellulosic substrates between free enzyme versus enzyme bound to mobile enzyme sequestration platforms (mESP) (2020)
Collaboration Network
Top Collaborators
Chenguang Fan
University of Arkansas at Fayetteville
4 shared publications
In database
- Modifications of cellulose-based biomaterials for biomedical applications
- Characterizing lysine acetylation of glucokinase
- Studying lysine acetylation of citric acid cycle enzymes by genetic code expansion
- Functional consequences of lysine acetylation of phosphofructokinase isozymes
Ruben Michael Ceballos
University of Arkansas at Fayetteville
2 shared publications
In database
- Modifications of cellulose-based biomaterials for biomedical applications
- Comparisons of Catalytic Efficiency during the Reduction of Lignocellulosic Substrates between Free Enzyme and Enzyme bound to Mobile Enzyme Sequestration Platforms (MESP)
Rahatul Islam
West Virginia University (US)
2 shared publications
- In-Silico Prediction of Sirna to Silence the Sars-Cov-2 Omicron Variant Specifically Ba.4 and Ba.5: An Alternative to Traditional Therapeutics
- In silico prediction of siRNA to silence the SARS-CoV-2 omicron variant targeting BA.4, BA.5, BQ.1, BQ1.1. and XBB: an alternative to traditional therapeutics
Asif Shahriar
The University of Texas Rio Grande Valley (US)
2 shared publications
- In-Silico Prediction of Sirna to Silence the Sars-Cov-2 Omicron Variant Specifically Ba.4 and Ba.5: An Alternative to Traditional Therapeutics
- In silico prediction of siRNA to silence the SARS-CoV-2 omicron variant targeting BA.4, BA.5, BQ.1, BQ1.1. and XBB: an alternative to traditional therapeutics
Muhammad Ramiz Uddin
University of Oklahoma (US)
2 shared publications
- In-Silico Prediction of Sirna to Silence the Sars-Cov-2 Omicron Variant Specifically Ba.4 and Ba.5: An Alternative to Traditional Therapeutics
- In silico prediction of siRNA to silence the SARS-CoV-2 omicron variant targeting BA.4, BA.5, BQ.1, BQ1.1. and XBB: an alternative to traditional therapeutics
Mrityunjoy Acharjee
Stamford University Bangladesh (BD)
2 shared publications
- In-Silico Prediction of Sirna to Silence the Sars-Cov-2 Omicron Variant Specifically Ba.4 and Ba.5: An Alternative to Traditional Therapeutics
- In silico prediction of siRNA to silence the SARS-CoV-2 omicron variant targeting BA.4, BA.5, BQ.1, BQ1.1. and XBB: an alternative to traditional therapeutics
Md Mukhlesur Rahman Shepon
Shahjalal University of Science and Technology (BD)
2 shared publications
- In-Silico Prediction of Sirna to Silence the Sars-Cov-2 Omicron Variant Specifically Ba.4 and Ba.5: An Alternative to Traditional Therapeutics
- In silico prediction of siRNA to silence the SARS-CoV-2 omicron variant targeting BA.4, BA.5, BQ.1, BQ1.1. and XBB: an alternative to traditional therapeutics
Avishek Sarkar
Shahjalal University of Science and Technology (BD)
2 shared publications
- In-Silico Prediction of Sirna to Silence the Sars-Cov-2 Omicron Variant Specifically Ba.4 and Ba.5: An Alternative to Traditional Therapeutics
- In silico prediction of siRNA to silence the SARS-CoV-2 omicron variant targeting BA.4, BA.5, BQ.1, BQ1.1. and XBB: an alternative to traditional therapeutics
Xinyu Li
University of Arkansas at Fayetteville
2 shared publications
In database
- Characterizing lysine acetylation of glucokinase
- Functional consequences of lysine acetylation of phosphofructokinase isozymes
Qinglei Gan
University of Arkansas at Fayetteville
2 shared publications
In database
- Characterizing lysine acetylation of glucokinase
- Functional consequences of lysine acetylation of phosphofructokinase isozymes
Sohag Ahmed
West Virginia University (US)
1 shared publication
- In-Silico Prediction of Sirna to Silence the Sars-Cov-2 Omicron Variant Specifically Ba.4 and Ba.5: An Alternative to Traditional Therapeutics
Khosnur Jahan Aurin
1 shared publication
- In silico prediction of siRNA to silence the SARS-CoV-2 omicron variant targeting BA.4, BA.5, BQ.1, BQ1.1. and XBB: an alternative to traditional therapeutics
Similar Researchers
Based on overlapping research topics
Hideya Koizumi
Arkansas State University
Metabolism and Genetic Disorders
Protein Structure and Dynamics
Pharmacological Effects and Toxicity Studies
Mahmoud Kiaei
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Protein Structure and Dynamics
Pharmacological Effects and Toxicity Studies
Sumathi Subbiah
University of Arkansas at Fayetteville
Protein Structure and Dynamics
Microbial infections and disease research
Molecular Biology Techniques and Applications
Wei Zhuang
National Center for Toxicological Research
Metabolism and Genetic Disorders
Pharmacological Effects and Toxicity Studies
Molecular Biology Techniques and Applications
Richard Chastain
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Molecular Biology Techniques and Applications
Plant Physiology and Cultivation Studies
Kavinash Anandaraj
University of Arkansas at Fayetteville
Metabolism and Genetic Disorders
Protein Structure and Dynamics
Molecular Biology Techniques and Applications